Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04711434
Other study ID # B2020-059-01
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 1, 2020
Est. completion date December 31, 2025

Study information

Verified date January 2021
Source Sun Yat-sen University
Contact Peirong Ding, MD, Ph D
Phone 00862087343124
Email dingpr@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to explore the role of PD-1 Antibody in preventing adenomatous polyps and second primary tumors in patients with Lynch Syndrome. There two arms, one is the experimental arm (PD-1 antibody prevention group) and the other is the control arm (routine follow-up group). For the experimental group, Tripleitriumab (PD-1 antibody) is given every 3 months for a year.


Description:

Lynch syndrome (LS) is a hereditary cancer syndrome that causes the majority of hereditary CRC and approximately 3% of all CRC. LS significantly increases the risk for an individual to develop CRC during their lifetime. Individuals with LS also have an increased risk to develop extracolonic cancers, including endometrial, gastric, ovarian, upper urinary tract, small bowel, biliary tract, CNS, and certain types of skin cancer. Given the hereditary nature of this syndrome, preventing second primary tumors in patients with Lynch Syndrome after surgery to the primary site is very important. The purpose of this study is to prevent adenomatous polyps and second primary tumors using PD-1 antibody (Tripleitriumab) in patients with Lynch Syndrome. The primary outcome of this study is the incidence of intestinal adenomatous polyps and secondary primary tumors. The secondary outcomes are the incidence of colorectal adenomatous polyps greater than 1cm, incidence of high-grade colorectal polyps, treatment-related adverse events, disease-free Survival and overall Survival. There are two groups: the PD-1 antibody prevention group and the routine follow-up group. For the PD-1 antibody prevention group, participants will receive Toripalimab 240mg IV every 3 months for a year. For the routine follow-up group, there is no drug intervention. This whole study will take 5 years: the first year for recruiting and the latter four years for follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 260
Est. completion date December 31, 2025
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Lynch syndrome with germline variants of MLH1, MSH2, or EPCAM (pathogenic or likely pathogenic variants) 2. Necessary treatments have been done, such as surgery, chemotherapy, radiation therapy, etc. 3. Have a resection, including right hemicolectomy, left hemicolectomy, sigmoid colectomy, or anterior resection of rectal cancer, or endoscopic adenoma resection 4. Aged 18-70 years old 5. Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1 6. White blood cell (WBC) > 4000/mm3, Platelet count >100000/mm3, HB >10 g/dL 7. Serum glutamic-oxaloacetic transaminase (SGOT) < 1.5 × the upper limit of normal (ULN), Serum glutamic pyruvic transaminase (SGPT) < 1.5 × ULN prior to randomization, Total bilirubin (TBIL) < 1.5 mg/dL 8. Serum creatinine (Scr) <1.8 mg/dL Exclusion Criteria: 1. Lynch syndrome with germline variants of MSH6 and PMS2 2. Previous immunotherapy has been taken, such as anti-PD-1, anti-PD-L1, etc. 3. Long-term use of aspirin 4. Suffering from autoimmune diseases 5. Active infection with hepatitis B or hepatitis C (high copy number of viral DNA) or human immunodeficiency virus (HIV) 6. Other clinically serious active infections (NCI-CTC 4.0) 7. With cachexia or organ dysfunction 8. Suffering from seizures requiring treatment (such as steroids or antiepileptic therapy) 9. Unable to participate or complete the study due to substance abuse, or medical, psychological, or social disorder 10. Known allergy to any drugs in this study 11. Pregnant or nursing women, or women of childbearing potential who are not using adequate contraception 12. Any unstable condition or situation that could compromise the safety and compliance of participants. 13. Failure to sign an informed consent form

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PD-1 Antibody
Toripalimab: 240mg IV every 3 months for a year

Locations

Country Name City State
China Sun Yat-sen University, Cancer Center Guangzhou Guangdong

Sponsors (6)

Lead Sponsor Collaborator
Sun Yat-sen University Fujian Cancer Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, The Third Affiliated Hospital of Kunming Medical College.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage of patients from randomization to the first appearance of one of the following: adenomatous polyps or second primary tumors up to 5 years
Secondary The percentage of patients developing polyps greater than 1cm within 5 years from randomization up to 5 years
Secondary The percentage of patients developing high-grade polyps on pathology within 5 years from randomization. up to 5 years
Secondary Treatment-related adverse events Incidence and severity of adverse events as assessed by NCI CTCAE V4.0 up to 5 years
Secondary Effectiveness with different genotypes or phenotypes Estimated the percentage of patients with different genotypes or phenotypes not developing polyps or second primary tumors within 5 years from randomization. up to 5 years
Secondary Disease-free Survival defined as the time from randomization to the first appearance of one of the following: primary tumor recurrence, or death without cancer event; or censored at date of last follow-up up to 5 years
Secondary Overall Survival defined as the time from randomization to death from any cause. Participants who were alive or lost to follow-up at the time of the analysis were censored at the date they were last known to be alive up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00217737 - Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Phase 3
Completed NCT00905710 - Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Recruiting NCT04909671 - Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome. N/A
Recruiting NCT04379999 - Atorvastatin ± Aspirin in Lynch Syndrome Syndrome Early Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed NCT01845753 - Molecular Screening for Lynch Syndrome in Denmark
Completed NCT01216930 - Molecular Screening for Lynch Syndrome in Southern Denmark N/A
Not yet recruiting NCT05963191 - CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome N/A
Active, not recruiting NCT02912559 - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Phase 3
Recruiting NCT04978350 - Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study N/A
Active, not recruiting NCT03832985 - Pediatric Reporting of Adult-Onset Genomic Results Early Phase 1
Withdrawn NCT04778566 - Evaluating the Cologuard Test for Use in Lynch Syndrome
Completed NCT02570516 - NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome N/A
Completed NCT01823471 - I-Scan For Colon Polyp Detection In HNPCC N/A
Recruiting NCT02813824 - Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Phase 3
Recruiting NCT05078866 - Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients Phase 1/Phase 2
Recruiting NCT03744962 - MSI in Circulatory DNA of Endometrial Cancer
Completed NCT04131062 - Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants N/A
Recruiting NCT05704010 - Videocapsule Endoscopy in Lynch Syndrome N/A